Hepatitis numbers can shift fast, and 2025 is a reminder that progress depends on details, not averages. Around 354 million people were living with chronic hepatitis B in 2016 and another 57.3 million had chronic hepatitis C by 2022, but the gap between reported and estimated infections is where the real story starts. When you compare patterns like undiagnosed HCV, vaccination impact on childhood HBV, and sanitation driven HAV outbreaks, the same virus looks totally different across countries.
Key Takeaways
- Globally, approximately 354 million people were living with chronic hepatitis B (HBV) infection in 2016, according to WHO estimates
- In 2022, the global prevalence of chronic hepatitis C (HCV) infection was estimated at 57.3 million people, a reduction from previous years due to treatment scale-up
- Hepatitis A virus (HAV) incidence worldwide was about 1.4 million cases in 2016, with 7,134 deaths primarily in regions with poor sanitation
- Universal HBV infant vaccination prevents 75-95% of perinatal transmissions globally since 1992
- Hepatitis B vaccine efficacy is 95% in preventing chronic infection when given at birth +2+6 months
- HAV vaccine provides 94-100% protection for 20+ years after two doses in adults
- Early acute HBV symptoms appear in 30-50% of adults, including fever, fatigue, and jaundice after 60-150 day incubation
- Chronic HCV leads to extrahepatic manifestations like cryoglobulinemia in 40-60% of patients over time
- HAV acute phase jaundice occurs in 70% of symptomatic cases, lasting 1-3 weeks
- HBV vertical transmission rate without intervention is 90% if mother is HBeAg-positive
- Injection drug use accounts for 23% of new HBV infections globally per 2015 meta-analysis
- Sexual transmission of HAV increased 10-fold in US MSM from 2013-2018 due to pre-exposure prophylaxis use
- Direct-acting antivirals (DAAs) cure >95% of chronic HCV genotype 1 infections in 12 weeks
- Tenofovir disoproxil fumarate suppresses HBV DNA to undetectable in 93-98% of patients at 48 weeks
- Interferon-alpha for HBV achieves HBeAg seroconversion in 30-40% after 48 weeks, but with 30% dropout rate
Chronic hepatitis B and C still affect hundreds of millions worldwide, but vaccination and treatment are rapidly cutting risk.
Related reading
01 · Category
Prevalence and Incidence24 stats
01
Globally, approximately 354 million people were living with chronic hepatitis B (HBV) infection in 2016, according to WHO estimates
02
In 2022, the global prevalence of chronic hepatitis C (HCV) infection was estimated at 57.3 million people, a reduction from previous years due to treatment scale-up
03
Hepatitis A virus (HAV) incidence worldwide was about 1.4 million cases in 2016, with 7,134 deaths primarily in regions with poor sanitation
04
In the United States, acute HBV cases reported in 2021 totaled 2,890, but estimated actual infections were 25,200 after adjusting for underreporting
05
Chronic HCV prevalence in Egypt reached 5.3% of the population (about 4.5 million people) in 2018 before mass treatment campaigns
06
In sub-Saharan Africa, HBV prevalence among adults is 6.1%, affecting over 60 million people in 2020 estimates
07
Global HAV seroprevalence in children under 15 years is over 90% in high-endemicity areas like South Asia
08
In 2019, 58 million people in the WHO Western Pacific Region lived with chronic HBV, representing 59% of global burden
09
HCV incidence in the US from injection drug use accounted for 33% of new cases in 2020
10
Mongolia has the highest HBV prevalence at 11.8% among adults in 2021 surveys
11
In Europe, chronic HBV affected 7 million people in 2017, with highest rates in Eastern Europe at 2.5%
12
Acute HAV outbreaks in the US from 2016-2020 reported 33,000 cases, mostly among homeless and drug users
13
Global HDV superinfection on HBV affects 12-20 million people, primarily in Amazon Basin and Eastern Europe
14
In Pakistan, HCV prevalence is 2.5% nationally, with 12.4 million infected in 2017
15
In 2022, 3.6 million people received HCV testing and 1.3 million treatment through scale-up
16
Chronic HBV in children under 5 dropped 68% from 2015-2021 due to vaccination, to 6.0% prevalence
17
US acute HCV cases rose 26% from 2020-2021 to 66,700 estimated infections
18
In India, HCV prevalence among blood donors is 0.44%, with 12 million total infected estimated 2020
19
HDV prevalence on HBV in Italy fell from 20% in 1980s to 8% in 2019 cohorts
20
Global HEV genotype 1 causes 3.4 million symptomatic cases yearly in Asia
21
Cameroon HBV prevalence is 10.6% in general population, highest in Africa 2021 survey
22
Europe HCV chronic cases estimated 4.4 million in 2018, with 57% undiagnosed
23
US chronic HBV prevalence stable at 0.3-0.4% or 800,000-2.2 million adults 2020
24
Vietnam eliminated mother-to-child HBV transmission as first country in 2019 with 89% coverage
Interpretation
Prevalence and Incidence Interpretation
Globally, hepatitis is a staggering, silent pandemic that highlights both our medical triumphs—like vaccines and treatments dramatically reducing cases—and our profound failures in sanitation, prevention, and equitable healthcare access.
02 · Category
Prevention and Vaccination24 stats
01
Universal HBV infant vaccination prevents 75-95% of perinatal transmissions globally since 1992
02
Hepatitis B vaccine efficacy is 95% in preventing chronic infection when given at birth +2+6 months
03
HAV vaccine provides 94-100% protection for 20+ years after two doses in adults
04
Safe injection practices could prevent 10 million new HCV infections by 2030 per WHO modeling
05
HBV screening of pregnant women with antiviral prophylaxis reduces transmission to <5%
06
Hand hygiene and sanitation avert 50% of HAV cases in moderate-endemic settings
07
Opioid substitution therapy reduces HCV incidence by 50% among people who inject drugs
08
HEV prevention via cooking pork to 71°C kills genotype 3 virus in 99% of cases
09
Needle-syringe programs halve HIV and HCV transmission risk in 28 studies meta-analysis
10
3-dose HBV series coverage reached 84% globally in 2021, preventing 320 million chronic infections since 1990
11
Post-exposure HBV prophylaxis with HBIG + vaccine is 85-95% effective within 24 hours
12
HCV treatment as prevention models predict 60% incidence drop with 10% annual treatment coverage
13
Chlorination of water at 1mg/L free chlorine inactivates HAV after 16 minutes contact time
14
HBV vaccine birth dose alone prevents 75% mother-to-child transmission if given within 24 hours
15
Global HAV vaccination in children could avert 157,000 deaths by 2030 per modeling
16
Global HBV vaccination coverage at birth dose 42% in 2021, up from 31% in 2010
17
HAV vaccine boosters unnecessary as immunity persists >25 years at 100% seropositivity
18
Screen-and-treat for HCV in prisons reduces prevalence 30% in 3 years Australian study
19
Condom use reduces HBV sexual transmission by 70-90% in discordant couples
20
Point-of-care HCV RNA testing enables same-day DAA initiation, increasing cure 40%
21
HBV vaccine response in dialysis patients improves to 80% with double-dose schedule
22
Safe sex education in schools averts 25% of HAV outbreaks in adolescents
23
HEV vaccine (Hecolin) 100% efficacious against genotype 1 in phase III trial 2011
24
Universal precautions reduce nosocomial HBV by 80% in healthcare workers
Interpretation
Prevention and Vaccination Interpretation
Science has handed us a remarkably effective playbook to end viral hepatitis, and though it reads like a greatest hits of common sense—from vaccines and clean needles to cooked pork and chlorinated water—the sobering truth is that its full power remains locked by our collective failure to universally implement these brilliantly simple, life-saving measures.
03 · Category
Symptoms and Diagnosis25 stats
01
Early acute HBV symptoms appear in 30-50% of adults, including fever, fatigue, and jaundice after 60-150 day incubation
02
Chronic HCV leads to extrahepatic manifestations like cryoglobulinemia in 40-60% of patients over time
03
HAV acute phase jaundice occurs in 70% of symptomatic cases, lasting 1-3 weeks
04
HBV e antigen (HBeAg) positivity indicates high viral load and infectivity in 70-80% of chronic carriers initially
05
Liver biopsy in chronic hepatitis shows fibrosis staging from F0 (none) to F4 (cirrhosis) in 20-30% advancing annually untreated
06
HEV superacute liver failure risk is 25% in pregnant women during third trimester
07
Anti-HCV antibody seropositivity requires RNA confirmation as 25% are resolved spontaneously
08
Acute HDV symptoms mimic HBV but with higher fulminant failure rate of 5-10%
09
FibroScan elastography cutoff >7.0 kPa indicates significant fibrosis (F2+) in HBV with 85% accuracy
10
HAV IgM detection confirms acute infection with sensitivity 94-100% within 2 weeks of onset
11
Chronic HBV flares (ALT >5x ULN) occur in 20-30% annually on nucleoside therapy interruption
12
HCV genotype 1a prevalence in US is 60% among new diagnoses, affecting treatment choice
13
Decompensated cirrhosis symptoms like ascites appear in 50% of untreated chronic viral hepatitis cases after 20 years
14
HBV DNA levels >20,000 IU/mL in HBeAg-negative patients indicate active disease requiring therapy
15
Chronic HBV patients asymptomatic until cirrhosis in 30%, with fatigue in 40-60%
16
HCV acute symptoms resolve without jaundice in 80%, but 75% progress chronically
17
HDV coinfection accelerates HBV cirrhosis onset to 5-10 years vs 20-30 alone
18
APRI score >2.0 predicts cirrhosis with 77% accuracy in HCV, avoiding biopsy
19
HAV prodrome includes anorexia, nausea in 80% 2-10 days pre-jaundice
20
HBV immune complex glomerulonephritis occurs in 5-10% of chronic Asian children
21
HEV IgM sensitivity 94% for acute diagnosis, peaks at 1-2 weeks post-onset
22
Fibrosis-4 (FIB-4) index <1.45 rules out advanced fibrosis in HBV with 90% NPV
23
HCC surveillance with AFP + US detects early tumors in 65% of HBV cirrhotics
24
Polyarteritis nodosa in HBV affects 1-5% chronically, presenting with neuropathy
25
HCV RNA PCR detects viremia with limit 15 IU/mL sensitivity in 99% positives
Interpretation
Symptoms and Diagnosis Interpretation
While each virus flaunts its own menacing stats, from HAV's deceptive "flu" to HBV's silent sabotage and HCV's chronic artistry, their collective message is clear: viral hepatitis is a shape-shifting master of chaos, both overt and covert, whose true danger often lies not in the symptoms you see, but in the liver damage you don't.
More related reading
04 · Category
Transmission and Risk Factors24 stats
01
HBV vertical transmission rate without intervention is 90% if mother is HBeAg-positive
02
Injection drug use accounts for 23% of new HBV infections globally per 2015 meta-analysis
03
Sexual transmission of HAV increased 10-fold in US MSM from 2013-2018 due to pre-exposure prophylaxis use
04
HCV transmission via blood transfusion dropped 99% post-1992 screening in developed countries
05
Household contact transmission of HBV occurs in 30-60% of exposed children under 5 years
06
Nosocomial transmission of HCV in dialysis units reaches 1-5% per year in low-resource settings
07
Mother-to-child transmission of HEV genotype 1 in endemic areas has 1-2% risk without hygiene
08
Occupational needlestick injuries transmit HBV in 6-30% of cases if source is HBeAg-positive
09
Fecal-oral route accounts for 100% of HAV transmission, with contaminated water causing 50% of outbreaks
10
HDV transmission mirrors HBV, with 70-90% via parenteral routes in co-infection cases
11
Unsafe injections cause 2.3 million new HCV infections annually worldwide
12
Incarceration increases HCV acquisition risk by 5-fold due to drug use and tattoos
13
HBV sexual transmission risk per act is 1-60% unprotected with infected partner
14
Contaminated razors in barbershops transmit HCV at 1.5-7.5% risk per exposure in high-prevalence areas
15
Tattoo-related HBV transmission risk is 1:100,000 with modern sterile practices
16
HCV perinatal transmission risk is 5-6% if maternal viral load >10^6 IU/mL
17
Sharing straws for cocaine insufflation transmits HCV in 1-5% of chronic users per year
18
HBV survives on dry surfaces up to 7 days, facilitating fomite transmission at 1-10% risk
19
HEV waterborne outbreaks infect 10-50% of exposed populations in fecally contaminated sources
20
MSM HIV+ have 20-fold higher HBV acquisition risk without vaccination
21
Unsafe medical injections cause 39% of new HBV infections in Eastern Mediterranean Region
22
HCV transmission from mother to infant increases to 10% with HIV coinfection
23
Glove perforation during surgery transmits HBV in 1:300 exposures from carrier surgeons
24
HAV foodborne outbreaks from shellfish contaminate 20-50% of product in affected lots
Interpretation
Transmission and Risk Factors Interpretation
These statistics collectively read like a damning indictment of human behavior and systemic failure, showing us that while we can engineer near-perfect safety from blood transfusions, we are still alarmingly vulnerable to our own vices, shortcuts, and inequities.
05 · Category
Treatment and Management21 stats
01
Direct-acting antivirals (DAAs) cure >95% of chronic HCV genotype 1 infections in 12 weeks
02
Tenofovir disoproxil fumarate suppresses HBV DNA to undetectable in 93-98% of patients at 48 weeks
03
Interferon-alpha for HBV achieves HBeAg seroconversion in 30-40% after 48 weeks, but with 30% dropout rate
04
Pegylated interferon plus ribavirin cured 45% of HCV genotype 1 pre-DAA era in 2011 meta-analysis
05
HDV treatment with peg-IFN shows 25-40% sustained virologic response at 24 weeks post-therapy
06
Entecavir resistance develops in <1% of nucleoside-naive HBV patients after 5 years
07
Glecaprevir/pibrentasvir achieves 98% SVR12 in HCV GT1-6 without cirrhosis in 8 weeks
08
Liver transplantation 5-year survival for HBV cirrhosis is 80-90% with antiviral prophylaxis
09
Sofosbuvir/velpatasvir cures 99% of HCV in 12 weeks regardless of genotype or prior treatment
10
HEV chronic infection clearance with ribavirin occurs in 78% of immunocompromised patients
11
HBV reactivation risk on rituximab is 23% without prophylaxis per 2019 meta-analysis
12
DAA retreatment success for DAA-failure HCV is 90-96% with pangenotypic regimens
13
Ledipasvir/sofosbuvir SVR12 rate 99% in treatment-naive GT1 HCV without cirrhosis
14
Telbivudine HBeAg loss in 30% at 1 year vs 20% entecavir in HBeAg+ patients
15
Bulevirtide 10mg daily suppresses HDV RNA in 46% at 24 weeks phase II trial
16
DAA therapy post-liver transplant cures HCV in 90-95%, improving graft survival 20%
17
Tenofovir alafenamide matches TDF efficacy with 20% less bone/kidney toxicity at 96 weeks
18
Ribavirin dose reduction in HCV improves adherence, maintaining 92% SVR in GT1
19
Lamivudine resistance in HBV reaches 70% by year 5 without monitoring
20
Sofosbuvir monotherapy ineffective at 10% SVR, requires combos for resistance barrier
21
Mycophenolate prophylaxis prevents HDV recurrence post-transplant in 80%
Interpretation
Treatment and Management Interpretation
While we've traded the grueling marathon of old hepatitis therapies for nearly surgical precision with modern drugs, the ghost of treatment past lingers in the form of resistance, side effects, and the stark reminder that our victories are fragile without vigilance.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Hepatitis Statistics. Gitnux. https://gitnux.org/hepatitis-statistics
MLA
Thomas Lindqvist. "Hepatitis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hepatitis-statistics.
Chicago
Thomas Lindqvist. 2026. "Hepatitis Statistics." Gitnux. https://gitnux.org/hepatitis-statistics.
Sources & references
11 datasets cited across this report · attribution is report-level
+1 additional datasets cited (not shown individually)